China SXT Pharmaceuticals (SXTC) Current Deferred Revenue: 2018-2025
- China SXT Pharmaceuticals' Current Deferred Revenue rose 295.81% to $5,240 in Q3 2025 from the same period last year, while for Sep 2025 it was $5,240, marking a year-over-year increase of 295.81%. This contributed to the annual value of $58,627 for FY2025, which is 68.76% down from last year.
- Latest data reveals that China SXT Pharmaceuticals reported Current Deferred Revenue of $5,240 as of Q3 2025, which was down 91.06% from $58,627 recorded in Q1 2025.
- China SXT Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $257,449 during Q1 2021, with a 5-year trough of -$42,994 in Q3 2021.
- Its 3-year average for Current Deferred Revenue is $74,929, with a median of $46,906 in 2023.
- Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 965.99% in 2023, then slumped by 107.61% in 2024.
- Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Current Deferred Revenue stood at -$42,994 in 2021, then soared by 90.55% to -$4,063 in 2022, then surged by 965.99% to $35,185 in 2023, then tumbled by 107.61% to -$2,676 in 2024, then surged by 295.81% to $5,240 in 2025.
- Its last three reported values are $5,240 in Q3 2025, $58,627 for Q1 2025, and -$2,676 during Q3 2024.
